137 related articles for article (PubMed ID: 23795724)
21. Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression.
Kim HY; Jung HU; Yoo SH; Yoo KS; Cheong J; Park BS; Yun I; Yoo YH
Cancer Lett; 2014 Dec; 355(1):61-9. PubMed ID: 25218348
[TBL] [Abstract][Full Text] [Related]
22. Development of cisplatin-loaded hydrogels for trans-portal vein chemoembolization in an orthotopic liver cancer mouse model.
Yang X; Yeung WO; Tan KV; Ng TK; Pang L; Zhou J; Li J; Li C; Li X; Lo CM; Kao WJ; Man K
Drug Deliv; 2021 Dec; 28(1):520-529. PubMed ID: 33685316
[TBL] [Abstract][Full Text] [Related]
23. RCC2 contributes to tumor invasion and chemoresistance to cisplatin in hepatocellular carcinoma.
Chen Q; Jiang P; Jia B; Liu Y; Zhang Z
Hum Cell; 2020 Jul; 33(3):709-720. PubMed ID: 32239438
[TBL] [Abstract][Full Text] [Related]
24. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
Seki A; Hori S
Cardiovasc Intervent Radiol; 2012 Jun; 35(3):555-62. PubMed ID: 21562932
[TBL] [Abstract][Full Text] [Related]
25. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma.
Jang JW; Park YM; Bae SH; Choi JY; Yoon SK; Chang UI; Nam SW; Kim BS
Cancer Chemother Pharmacol; 2004 Nov; 54(5):415-20. PubMed ID: 15235823
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
28. Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins?
Biolato M; Marrone G; Racco S; Di Stasi C; Miele L; Gasbarrini G; Landolfi R; Grieco A
Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):356-62. PubMed ID: 20496548
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells.
Jung EU; Yoon JH; Lee YJ; Lee JH; Kim BH; Yu SJ; Myung SJ; Kim YJ; Lee HS
Cancer Lett; 2010 Dec; 298(1):9-15. PubMed ID: 20573444
[TBL] [Abstract][Full Text] [Related]
30. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization.
Wang B; Xu H; Gao ZQ; Ning HF; Sun YQ; Cao GW
Acta Radiol; 2008 Jun; 49(5):523-9. PubMed ID: 18568538
[TBL] [Abstract][Full Text] [Related]
31. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
32. Vigilin is overexpressed in hepatocellular carcinoma and is required for HCC cell proliferation and tumor growth.
Yang WL; Wei L; Huang WQ; Li R; Shen WY; Liu JY; Xu JM; Li B; Qin Y
Oncol Rep; 2014 May; 31(5):2328-34. PubMed ID: 24676454
[TBL] [Abstract][Full Text] [Related]
33. Differential sensitivity of hepatocellular carcinoma cells to suppression of hepatocystin transcription under hypoxic conditions.
Yoo JJ; Lee DH; Cho Y; Cho EJ; Lee JH; Yu SJ; Kim YJ; Kim CY; Yoon JH
J Bioenerg Biomembr; 2016 Dec; 48(6):581-590. PubMed ID: 27640193
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
[TBL] [Abstract][Full Text] [Related]
35. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion.
Kim KM; Kim JH; Park IS; Ko GY; Yoon HK; Sung KB; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2009 May; 24(5):806-14. PubMed ID: 19207681
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma.
Wu XZ; Xie GR; Chen D
J Gastroenterol Hepatol; 2007 Aug; 22(8):1178-82. PubMed ID: 17559361
[TBL] [Abstract][Full Text] [Related]
37. Oxygen carrier YQ23 can enhance the chemotherapeutic drug responses of chemoresistant esophageal tumor xenografts.
Lee NP; Chan KT; Choi MY; Lam HY; Tung LN; Tzang FC; Han H; Lam IP; Kwok SY; Lau SH; Man C; Tong DK; Wong BL; Law S
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1199-207. PubMed ID: 26553104
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice.
Lin WH; Yeh SH; Yeh KH; Chen KW; Cheng YW; Su TH; Jao P; Ni LC; Chen PJ; Chen DS
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11937-11942. PubMed ID: 27702890
[TBL] [Abstract][Full Text] [Related]
39. Increased metastatic potential of residual carcinoma after transarterial embolization in rat with McA-RH7777 hepatoma.
Wang GZ; Fang ZT; Zhang W; Qu XD; Qian S; Liu R; Wang JH
Oncol Rep; 2014 Jan; 31(1):95-102. PubMed ID: 24173823
[TBL] [Abstract][Full Text] [Related]
40. Effect of preoperative transcatheter arterial chemoembolization on apoptosis of hepatocellular carcinoma cells.
Xiao E; Li D; Shen S; Zhou S; Tan L; Wang Y; Luo J; Wu Y; Tan C; Liu H; Zhu H
Chin Med J (Engl); 2003 Feb; 116(2):203-7. PubMed ID: 12775230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
